{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T17:14:51Z","timestamp":1786986891507,"version":"build-2736575974"},"reference-count":36,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1016\/j.clml.2023.10.012","type":"journal-article","created":{"date-parts":[[2023,10,31]],"date-time":"2023-10-31T22:08:21Z","timestamp":1698790101000},"page":"187-193.e1","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Impact of Folinic Acid Dosing on Efficacy and Toxicity of High-Dose Methotrexate in Central Nervous System Lymphoma"],"prefix":"10.1016","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2414-3746","authenticated-orcid":false,"given":"Arnon","family":"Haran","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noa Gross","family":"Even-Zohar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michal","family":"Haran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eyal","family":"Lebel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shlomzion","family":"Aumann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adir","family":"Shaulov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9426-4482","authenticated-orcid":false,"given":"Moshe","family":"Gatt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boaz","family":"Nachmias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2023.10.012_bib0001","doi-asserted-by":"crossref","unstructured":"Calimeri, T., Steffanoni, S., Gagliardi, F., Chiara, A., and Ferreri, A.J.M. (2021). How we treat primary central nervous system lymphoma. ESMO Open 6. 10.1016\/j.esmoop.2021.100213.","DOI":"10.1016\/j.esmoop.2021.100213"},{"key":"10.1016\/j.clml.2023.10.012_bib0002","doi-asserted-by":"crossref","first-page":"2318","DOI":"10.1182\/blood-2013-06-453084","article-title":"How I treat CNS lymphomas","volume":"122","author":"Rubenstein","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.clml.2023.10.012_bib0003","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1016\/0277-5379(91)90269-J","article-title":"How much is too much? Folinic acid rescue dose in children with acute lymphoblastic leukaemia","volume":"27","author":"Borsi","year":"1991","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.clml.2023.10.012_bib0004","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1038\/sj.leu.2404404","article-title":"High leucovorin doses during high-dose methotrexate treatment may reduce the cure rate in childhood acute lymphoblastic leukemia","volume":"20","author":"Sk\u00e4rby","year":"2006","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2023.10.012_bib0005","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.3390\/cancers15051459","article-title":"A systematic review of high-dose methotrexate for adults with primary central nervous system lymphoma","volume":"15","author":"Villanueva","year":"2023","journal-title":"Cancers"},{"key":"10.1016\/j.clml.2023.10.012_bib0006","doi-asserted-by":"crossref","unstructured":"Lopez-Lopez, E., Autry, R.J., Smith, C., et al. Pharmacogenomics of intracellular methotrexate polyglutamates in patients\u2019 leukemia cells in vivo. J Clin Invest 130, 6600\u20136615. 10.1172\/JCI140797.","DOI":"10.1172\/JCI140797"},{"key":"10.1016\/j.clml.2023.10.012_bib0007","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1111\/bjh.15661","article-title":"Guidelines for the diagnosis and management of primary central nervous system diffuse large B-cell lymphoma","volume":"184","author":"Fox","year":"2019","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2023.10.012_bib0008","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1093\/neuonc\/noac196","article-title":"European Association of Neuro-Oncology (EANO) guidelines for treatment of primary central nervous system lymphoma (PCNSL)","volume":"25","author":"Hoang-Xuan","year":"2023","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.clml.2023.10.012_bib0009","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1186\/s13045-022-01356-7","article-title":"Evidence-based expert consensus on the management of primary central nervous system lymphoma in China","volume":"15","author":"Chen","year":"2022","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.clml.2023.10.012_bib0010","unstructured":"Common Terminology Criteria for Adverse Events (CTCAE) | Protocol Development | CTEP Available at: https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/ctc.htm. Accessed: May 10, 2023."},{"key":"10.1016\/j.clml.2023.10.012_bib0011","doi-asserted-by":"crossref","first-page":"2102","DOI":"10.1080\/10428194.2022.2064996","article-title":"Rituximab, methotrexate, procarbazine and lomustine (R-MPL) for the treatment of primary Central nervous system lymphoma","volume":"63","author":"Lebel","year":"2022","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2023.10.012_bib0012","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1038\/bjc.2011.357","article-title":"Age, gender, and racial differences in incidence and survival in primary CNS lymphoma","volume":"105","author":"Villano","year":"2011","journal-title":"Br J Cancer"},{"key":"10.1016\/j.clml.2023.10.012_bib0013","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1200\/JCO.2003.09.139","article-title":"Prognostic scoring system for primary CNS lymphomas: the International Extranodal Lymphoma Study Group experience","volume":"21","author":"Ferreri","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2023.10.012_bib0014","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1159\/000511208","article-title":"Consolidation treatment for primary central nervous system lymphoma: which modality for whom?","volume":"144","author":"Bairey","year":"2020","journal-title":"Acta Haematol"},{"key":"10.1016\/j.clml.2023.10.012_bib0015","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1002\/hon.2037","article-title":"Salvage chemoimmunotherapy with rituximab, ifosfamide and etoposide (R-IE regimen) in patients with primary CNS lymphoma relapsed or refractory to high-dose methotrexate-based chemotherapy","volume":"31","author":"Mappa","year":"2013","journal-title":"Hematol Oncol"},{"key":"10.1016\/j.clml.2023.10.012_bib0016","first-page":"345","article-title":"Optimization of high-dose methotrexate with leucovorin rescue therapy in the L1210 leukemia and sarcoma 180 murine tumor models","volume":"38","author":"Sirotnak","year":"1978","journal-title":"Cancer Res"},{"key":"10.1016\/j.clml.2023.10.012_bib0017","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1080\/08880010390242898","article-title":"Progression of osteosarcoma after high-dose methotrexate: over-rescue by folinic acid","volume":"20","author":"Cohen","year":"2003","journal-title":"Pediatr Hematol Oncol"},{"key":"10.1016\/j.clml.2023.10.012_bib0018","doi-asserted-by":"crossref","first-page":"4477","DOI":"10.1182\/blood-2007-09-112920","article-title":"Risk-adjusted therapy of acute lymphoblastic leukemia can decrease treatment burden and improve survival: treatment results of 2169 unselected pediatric and adolescent patients enrolled in the trial ALL-BFM 95","volume":"111","author":"M\u00f6ricke","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.clml.2023.10.012_bib0019","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1016\/j.mehy.2013.08.027","article-title":"Challenging the clinical relevance of folinic acid over rescue after high dose methotrexate (HDMTX)","volume":"81","author":"Cohen","year":"2013","journal-title":"Med Hypotheses"},{"key":"10.1016\/j.clml.2023.10.012_bib0020","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1097\/00043426-200403000-00004","article-title":"Defining the appropriate dosage of folinic acid after high-dose methotrexate for childhood acute lymphatic leukemia that will prevent neurotoxicity without rescuing malignant cells in the central nervous system","volume":"26","author":"Cohen","year":"2004","journal-title":"J Pediatr Hematol Oncol"},{"key":"10.1016\/j.clml.2023.10.012_bib0021","doi-asserted-by":"crossref","first-page":"e217","DOI":"10.1016\/S2352-3026(16)00036-3","article-title":"Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trial","volume":"3","author":"Ferreri","year":"2016","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.clml.2023.10.012_bib0022","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1200\/JCO.2015.64.8634","article-title":"Phase I and II study of induction chemotherapy with methotrexate, rituximab, and temozolomide, followed by whole-brain radiotherapy and postirradiation temozolomide for primary CNS lymphoma: NRG Oncology RTOG 0227","volume":"34","author":"Glass","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2023.10.012_bib0023","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1002\/ajh.23812","article-title":"A phase 1 dose escalation study of idarubicin combined with methotrexate, vindesine, and prednisolone for untreated elderly patients with primary central nervous system lymphoma: the GOELAMS LCP 99 trial","volume":"89","author":"Olivier","year":"2014","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2023.10.012_bib0024","doi-asserted-by":"crossref","first-page":"4489","DOI":"10.1200\/JCO.2003.04.056","article-title":"Primary central nervous system lymphoma: results of a pilot and phase II study of systemic and intraventricular chemotherapy with deferred radiotherapy","volume":"21","author":"Pels","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2023.10.012_bib0025","doi-asserted-by":"crossref","first-page":"3971","DOI":"10.1200\/JCO.2013.50.4910","article-title":"Rituximab, methotrexate, procarbazine, and vincristine followed by consolidation reduced-dose whole-brain radiotherapy and cytarabine in newly diagnosed primary CNS lymphoma: final results and long-term outcome","volume":"31","author":"Morris","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2023.10.012_bib0026","doi-asserted-by":"crossref","DOI":"10.3324\/haematol.2022.280670","article-title":"The first achievement of complete remission in childhood leukemia by treatment with the folic acid antagonist aminopterin","volume":"107","author":"Izraeli","year":"2022","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2023.10.012_bib0027","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1093\/ajcn\/nqx076","article-title":"Folate and cancer: a tale of Dr. Jekyll and Mr. Hyde?","volume":"107","author":"Kim","year":"2018","journal-title":"Am J Clin Nutr"},{"key":"10.1016\/j.clml.2023.10.012_bib0028","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1136\/gut.2005.085480","article-title":"Low folate levels may protect against colorectal cancer","volume":"55","author":"Guelpen","year":"2006","journal-title":"Gut"},{"key":"10.1016\/j.clml.2023.10.012_bib0029","doi-asserted-by":"crossref","first-page":"2351","DOI":"10.1001\/jama.297.21.2351","article-title":"Folic acid for the prevention of colorectal adenomas: a randomized clinical trial","volume":"297","author":"Cole","year":"2007","journal-title":"JAMA"},{"key":"10.1016\/j.clml.2023.10.012_bib0030","article-title":"Can folate replacement induce lymphoma progression?","volume":"2018","author":"Ariyoshi","year":"2018","journal-title":"BMJ Case Rep"},{"key":"10.1016\/j.clml.2023.10.012_bib0031","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1038\/bjc.2017.11","article-title":"High folic acid diet enhances tumour growth in PyMT-induced breast cancer","volume":"116","author":"Hansen","year":"2017","journal-title":"Br J Cancer"},{"key":"10.1016\/j.clml.2023.10.012_bib0032","first-page":"3191","article-title":"Chemopreventive effects of dietary folate on intestinal polyps in Apc+\/\u2212 Msh2\u2212\/\u2212 Mice1","volume":"60","author":"Song","year":"2000","journal-title":"Cancer Res"},{"key":"10.1016\/j.clml.2023.10.012_bib0033","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1038\/sj.bjc.6605559","article-title":"Methotrexate area under the curve is an important outcome predictor in patients with primary CNS lymphoma: a pharmacokinetic\u2013pharmacodynamic analysis from the IELSG no. 20 trial","volume":"102","author":"Joerger","year":"2010","journal-title":"Br J Cancer"},{"key":"10.1016\/j.clml.2023.10.012_bib0034","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.3109\/10428194.2011.585527","article-title":"Methotrexate area under the curve as a prognostic factor in primary central nervous system lymphoma treated with immunochemoradiotherapy","volume":"52","author":"Morris","year":"2011","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2023.10.012_bib0035","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1038\/sj.bjc.6601472","article-title":"Area under the curve of methotrexate and creatinine clearance are outcome-determining factors in primary CNS lymphomas","volume":"90","author":"Ferreri","year":"2004","journal-title":"Br J Cancer"},{"key":"10.1016\/j.clml.2023.10.012_bib0036","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.3109\/10428194.2013.840780","article-title":"High incidence of methotrexate associated renal toxicity in patients with lymphoma: a retrospective analysis","volume":"55","author":"May","year":"2014","journal-title":"Leuk Lymphoma"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265023021602?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265023021602?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,2,29]],"date-time":"2024-02-29T17:19:41Z","timestamp":1709227181000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265023021602"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":36,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["S2152265023021602"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2023.10.012","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Impact of Folinic Acid Dosing on Efficacy and Toxicity of High-Dose Methotrexate in Central Nervous System Lymphoma","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2023.10.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}